[Treatment of spinal and bulbar muscular atrophy].
作者信息
Adachi Hiroaki, Katsuno Masahisa, Sobue Gen
机构信息
Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku Nagoya 466-8550, Japan.
出版信息
No To Shinkei. 2004 Sep;56(9):772-9.
PMID:15552866
Abstract
摘要
相似文献
1
[Treatment of spinal and bulbar muscular atrophy].
No To Shinkei. 2004 Sep;56(9):772-9.
2
Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.
Ann Neurol. 2009 Feb;65(2):140-50. doi: 10.1002/ana.21540.
3
Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy.
Nat Med. 2003 Jun;9(6):768-73. doi: 10.1038/nm878. Epub 2003 May 18.
4
A case of spinal and bulbar muscular atrophy with high-stage and high-Gleason Score prostate cancer responded to maximal androgen blockade therapy.
J Androl. 2012 Jul-Aug;33(4):563-5. doi: 10.2164/jandrol.111.013698. Epub 2011 Sep 22.
5
[A mother and her son with autosomal dominant bulbar spinal muscular atrophy].
Rinsho Shinkeigaku. 1992 Sep;32(9):1038-40.
6
Anti-androgen treatment for spinal and bulbar muscular atrophy.
Ann Neurol. 2009 Feb;65(2):119-20. doi: 10.1002/ana.21633.
7
Targeting toxic proteins for turnover.
Nat Med. 2005 Oct;11(10):1052-3. doi: 10.1038/nm1005-1052.
8
Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy.
Hum Mol Genet. 2006 Jul 15;15(14):2225-38. doi: 10.1093/hmg/ddl148. Epub 2006 Jun 13.
9
Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy.
Am J Pathol. 1998 Sep;153(3):695-701. doi: 10.1016/S0002-9440(10)65612-X.
10
Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy.
Muscle Nerve. 2008 Aug;38(2):964-71. doi: 10.1002/mus.21077.
Zotero 插件